Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
“ Linagliptin also produced statistically significant dose-dependent reductions from baseline for glucose area under the effect curve over 3 hours after meal tolerance tests (-29.0 to -68.1 mg × h/dL; P < 0.05 for all 3 linagliptin groups).”
“Furthermore, linagliptin treatment for 3 months reduced serum levels of both glucose and insulin at 2 h, relative to voglibose, in the age-, sex-, and baseline-adjusted model.”
“The data in Table 4 show that compared with placebo, linagliptin monotherapy reduced postprandial glucose by −1.95 mmol/l (95% CI: −5.14, −1.24) [1].”
Diabetes, obesity & metabolism • 2012 | View Paper
“In this study, monotherapy with either APD668 or linagliptin caused a reduction in the levels of ALT, AST, glucose , cholesterol and epididymal fat mass but the effect was more pronounced upon treatment with combination of both drugs.”
Biochemical and biophysical research communications • 2018 | View Paper
“Conclusion Linagliptin and liraglutide inhibit glucose- and Ang II-induced collagen formation in cardiac fibroblasts via activation of the ERK/NF-κB/pathway.”
“Glycated hemoglobin (−0.22%; P = 0.0021), fasting plasma glucose (−0.6 mmol/L; P = 0.0283), and glucose (AUEC0–3h) (−5.9 mmol/h/L; P < 0.0001) improved significantly with linagliptin versus placebo.”